3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Uterine Cervical Neoplasms
1
Skin Neoplasms
1
Neoplasm Metastasis
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Basal Cell Carcinoma of the Head and Neck
1
Interventions
pembrolizumab
19
Nivolumab
16
Cyclophosphamide
9
Specimen Handling
7
Ipilimumab
7
atezolizumab
6
fludarabine
5
Magnetic Resonance Spectroscopy
5
durvalumab
3
avelumab
3
X-Rays
3
Biopsy
3
ulixertinib
2
sargramostim
2
poly ICLC
2
lenvatinib
2
epacadostat
2
enzalutamide
2
cemiplimab
2
cabozantinib
2
budigalimab
2
aldesleukin
2
Trastuzumab
2
Sirolimus
2
Paclitaxel
2
Melphalan
2
Interleukin-2
2
Immunoglobulin G
2
Immune Checkpoint Inhibitors
2
Docetaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Tissue Banks
×
Dermatologic
×
Clear all
NCT06349642
2026-03-12
ELEPHAS-04
Mayo Clinic
Recruiting
324 enrolled